3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Myeloid
1
CNS
1
Conditions
Leukemia, Myeloid, Acute
21
Precursor Cell Lymphoblastic Leukemia-Lymphoma
20
Myelodysplastic Syndromes
19
Lymphoma, Non-Hodgkin
17
Leukemia, Lymphocytic, Chronic, B-Cell
15
Hodgkin Disease
15
Graft vs Host Disease
13
Lymphoma, Mantle-Cell
12
Leukemia
12
Multiple Myeloma
11
Lymphoma, Large B-Cell, Diffuse
11
Sarcoma
10
Lymphoma
10
Lymphoma, Follicular
9
Lymphoma, B-Cell, Marginal Zone
9
Burkitt Lymphoma
9
Myeloproliferative Disorders
8
Waldenstrom Macroglobulinemia
7
Tuberous Sclerosis
7
Neoplasms
7
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Hematologic Neoplasms
7
Congenital Abnormalities
7
Primary Myelofibrosis
6
Lymphoma, Large-Cell, Immunoblastic
6
Leukemia, Myelomonocytic, Chronic
6
Leukemia, Myeloid, Chronic-Phase
6
Leukemia, Myeloid, Accelerated Phase
6
Breast Neoplasms
6
Osteosarcoma
5
Interventions
Bevacizumab
10
Magnetic Resonance Spectroscopy
9
Temozolomide
8
Cyclophosphamide
8
Etoposide
7
X-Rays
6
Phantoms, Imaging
6
Specimen Handling
5
Nuclear Medicine Department, Hospital
5
Cisplatin
5
Radiotherapy
4
Irinotecan
4
Filgrastim
4
Carboplatin
4
Biopsy
4
Erlotinib Hydrochloride
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
sargramostim
2
palbociclib
2
olaparib
2
larotrectinib
2
ivosidenib
2
etoposide phosphate
2
erdafitinib
2
ensartinib
2
Vincristine
2
Vemurafenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Ependymoma
×
Sirolimus
×
Clear all
NCT02574728
2026-03-02
AflacST1502
Emory University
Phase 2
Active not recruiting
46 enrolled